Pembrolizumab vs Ranitidine
Pembrolizumab vs Ranitidine: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Ranitidine.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Ranitidine: Competitive H2 receptor antagonist.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days; Ranitidine — 2-3 hours.
Chemical Properties
Molecular Formula: Ranitidine — C13H22N4O3S.
Molecular Weight: Ranitidine — 314.4050 g/mol.
Type: Pembrolizumab — Antibody; Ranitidine — Small molecule.